Alok Sonig served as Executive Vice President and Group President, Pharmaceuticals of Baxter International. He joined Baxter in 2022 from Lupin, Inc. and was appointed to lead the Pharmaceuticals business as Group President in 2023, having initially served as president of that business. He brings more than 25 years of experience across the life sciences industry.
Before Baxter, Mr. Sonig served as U.S. Chief Executive Officer and Global Head of R&D and Biosimilars at Lupin, Inc. Earlier, he was Chief Executive Officer of Developed Markets (the U.S., Canada, Europe, and Japan) at Dr. Reddy's Laboratories, and he spent more than 15 years at Bristol Myers Squibb, where he held positions of increasing responsibility in general management, global strategy, and marketing.
On November 5, 2025, Mr. Sonig notified the company of his decision to resign as Executive Vice President and Group President, Pharmaceuticals, effective December 1, 2025, to join a company in the healthcare industry. He is a member of the Advisory Boards of the American University, Kogod School of Business, and of Sentry Sciences, Inc., and a member of the Board of the Southern Asian Pharmaceutical Council.